Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Equivalents: 2013-2024

Historic Cash & Equivalents for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $57.3 million.

  • Fortress Biotech's Cash & Equivalents rose 46.50% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.2 million, marking a year-over-year increase of 46.50%. This contributed to the annual value of $57.3 million for FY2024, which is 29.24% down from last year.
  • According to the latest figures from FY2024, Fortress Biotech's Cash & Equivalents is $57.3 million, which was down 29.24% from $80.9 million recorded in FY2023.
  • Fortress Biotech's 5-year Cash & Equivalents high stood at $305.7 million for FY2021, and its period low was $57.3 million during FY2024.
  • In the last 3 years, Fortress Biotech's Cash & Equivalents had a median value of $80.9 million in 2023 and averaged $105.5 million.
  • In the last 5 years, Fortress Biotech's Cash & Equivalents skyrocketed by 70.51% in 2020 and then plummeted by 54.60% in 2023.
  • Yearly analysis of 5 years shows Fortress Biotech's Cash & Equivalents stood at $233.4 million in 2020, then skyrocketed by 31.02% to $305.7 million in 2021, then plummeted by 41.69% to $178.3 million in 2022, then tumbled by 54.60% to $80.9 million in 2023, then fell by 29.24% to $57.3 million in 2024.